Literature DB >> 10867106

Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease.

N E Lepor1, S B Gross, W L Daley, B A Samuels, M J Rizzo, S P Luko, A Hickey, N A Buchbinder, T Z Naqvi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10867106     DOI： 10.1016/s0002-9149(00)00840-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  5 in total

Review 1.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Risk of valvular heart disease associated with use of fenfluramine.

Authors:  Paul N Hopkins; Gerald I Polukoff
Journal:  BMC Cardiovasc Disord       Date:  2003-06-11       Impact factor: 2.298

Review 4.  Appetite suppressants and valvular heart disease - a systematic review.

Authors:  Yoon K Loke; Sheena Derry; Angharad Pritchard-Copley
Journal:  BMC Clin Pharmacol       Date:  2002-08-23

5.  Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study.

Authors:  Wyman W Lai; Bradley S Galer; Pierre C Wong; Gail Farfel; Milka Pringsheim; Martin G Keane; Anupam Agarwal
Journal:  Epilepsia       Date:  2020-08-18       Impact factor: 5.864
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.